Endocyte (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Endocyte

Founded 1996

West Lafayette, United States 16 employees Debt Financing Total: $114.35M Biotechnology, Health Care +1

Endocyte is a biopharmaceutical company and a leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Founded in 1996, Endocyte operates within the industries of Biotechnology, Health Care, and Pharmaceutical, with its headquarters located in the United States. The company's last investment was an $8.10M Debt Financing investment at 27 December 2010. The investor information is not provided. Overall, Endocyte's focus on personalized cancer treatment and its advancements in targeted therapies exhibit strong potential for addressing unmet medical needs, making it an intriguing prospect for potential venture capitalist investment.

Funding Stage	Amount	Investors	Lead Investors	Date
Debt Financing	••••••	-		27 Dec 2010
Venture Round	••••••	2	•••• ••••	30 Aug 2010
Series C	••••••	6		19 Jan 2010
Series C	••••••	6		26 Mar 2007
Venture Round	••••••	6		13 Nov 2006

Funding Stage

Amount

Investors

Lead Investors

Date

Debt Financing

••••••

27 Dec 2010

Venture Round

••••••

•••• ••••

30 Aug 2010

Series C

••••••

19 Jan 2010

Series C

••••••

26 Mar 2007

Venture Round

••••••

13 Nov 2006

FAQ About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate...

Endocyte was founded in 1996.

Endocyte is headquartered in West Lafayette, United States.

Endocyte operates in the following industries: Biotechnology, Health Care, Pharmaceutical.

Endocyte has approximately 16 employees.

Endocyte has completed 7 funding rounds, raising a total of $114.35M. The latest funding stage is Debt Financing.

Top alternatives and competitors to Endocyte include Convergent Therapeutics, Inc., Focal Healthcare, Actinium Pharmaceuticals, Inc., Molecular Insight Pharmaceuticals, Aethon Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Endocyte and Convergent Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Endocyte

General Information

Track Endocyte

Discover More

About Endocyte

Funding Rounds & Investors (7)

Endocyte Alternatives & Competitors

FAQ About Endocyte

Don't just browse. Track.